In a statement released on November 5, 2026, the MDA affirmed that the health, safety, and well-being of people living with SMA remain its highest priority. The organization noted that it is aware of these reports and understands the urgency families feel to access additional information to make informed treatment and monitoring decisions. The MDA stated that it is seeking additional information, reviewing available scientific and safety data with clinical and research experts, and has reached out to Novartis, the manufacturer of Zolgensma.
Gene therapy represents a significant advancement in the treatment of genetic diseases, including SMA. For many individuals and families, these advances have brought meaningful progress, new possibilities, and a changed disease course for conditions that previously had limited treatment options. However, the MDA emphasized that gene therapy is a complex and evolving field. Understanding both its benefits and potential long-term risks requires continued research, careful monitoring, and open communication between healthcare providers, researchers, and patients.
At present, the MDA indicated that limited information is available regarding the specific details of these reports. Key uncertainties remain, including the timing of the events, the nature of the tumors identified, and whether any future monitoring of treated individuals will become appropriate. The organization stressed the importance of transparency and science-based information as more evidence emerges. Families with immediate questions or concerns about their treatment history, potential risks, or recommended monitoring are encouraged to speak with their healthcare providers, who can offer guidance based on individual circumstances.
The MDA also recognized the important work of researchers, clinicians, and companies advancing these treatments. The organization believes that continued collaboration and transparency are essential to sustaining progress and maintaining the trust of the communities these therapies are intended to serve. This response highlights the delicate balance public health organizations must strike: acknowledging new safety signals while preserving confidence in therapeutic innovations that have offered hope to patients with severe neuromuscular conditions.
For those seeking further support, the MDA directs individuals to its Resource Center by phone or email. The statement serves as a pivotal moment in the post-approval lifecycle of Zolgensma, shifting the focus from initial efficacy data to long-term safety surveillance. As the MDA and Novartis continue to review the data, the next verified development will likely involve updated safety communications or specific monitoring recommendations for patients who have received the therapy.
